Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
SVRA - Savara, Inc.
Market Cap 477.26M P/E - EPS this Y -33.30% Ern Qtrly Grth -
Income -75.29M Forward P/E -12.61 EPS next Y 2.30% 50D Avg Chg 16.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 64.00%
Dividend N/A Price/Book 4.10 EPS next 5Y - 52W High Chg -8.00%
Recommedations 1.60 Quick Ratio 10.89 Shares Outstanding 164.60M 52W Low Chg 227.00%
Insider Own 4.73% ROA -38.80% Shares Float 105.42M Beta 0.96
Inst Own 92.97% ROE -79.48% Shares Shorted/Prior 10.25M/8.77M Price 3.53
Gross Margin - Profit Margin - Avg. Volume 632,946 Target Price 10.79
Oper. Margin - Earnings Date Nov 7 Volume 418,792 Change -1.12%
Healthcare | Biotechnology | United States
About Savara, Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.

Savara, Inc. News
12/18/24 Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
12/17/24 Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
09:18 AM Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)
11/22/24 Savara Announces New Employment Inducement Grant
11/22/24 Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
11/13/24 Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate
11/13/24 Savara Announces Participation in Upcoming Healthcare Conferences
11/12/24 Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
11/04/24 Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
10/22/24 Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV
10/01/24 Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
09/27/24 Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
09/24/24 Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
09/23/24 Savara to Host Analyst and Investor Webinar on September 30, 2024
09/08/24 Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
09/05/24 Exploring Grid Dynamics Holdings And Two High Growth Tech Stocks
09/03/24 Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
09/01/24 Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025?
08/15/24 Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
08/12/24 Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Pauls Matthew CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Dec 28 Sell 4.71 84,000 395,640 1,302,674 12/29/23
Lowrance David L CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Dec 28 Sell 4.7131 10,000 47,131 342,355 12/29/23
Elam Nevan C Director Director Dec 28 Sell 4.71 93,843 442,001 22,500 12/29/23
Elam Nevan C Director Director Dec 28 Option 1.21 53,758 65,047 116,343 12/29/23
Hawkins Richard J Director Director Dec 11 Option 0.82 10,841 8,890 12,741 12/12/23
Elam Nevan C Director Director Dec 11 Option 0.82 10,841 8,890 40,085 12/12/23
Yang Rick 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
Walker Paul Edward 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
SANDELL SCOTT D 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
Mathers Edward T 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
Makhzoumi Mohamad 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
Florence Anthony A. Jr. 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
Chang Carmen 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
Behbahani Ali 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
BASKETT FOREST 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
Growth Equity Opportunities 17... 10% Owner 10% Owner Jul 17 Buy 3.00 333,333 999,999 24,471,264 07/19/23
Pratt Raymond Dennis Chief Medical Office.. Chief Medical Officer Jun 26 Buy 2.93 6,500 19,045 160,000 06/27/23
RAMSAY DAVID A Director Director May 24 Buy 2.59 100,000 259,000 2,201,142 05/26/23
RAMSAY DAVID A Director Director Dec 23 Buy 1.47 19,000 27,930 2,065,142 12/28/22
Pratt Raymond Dennis Chief Medical Office.. Chief Medical Officer Dec 22 Buy 1.5434 3,500 5,402 153,500 12/22/22
RAMSAY DAVID A Director Director Dec 20 Buy 1.48 45,000 66,600 2,046,142 12/22/22
Hawkins Richard J Director Director Dec 07 Option 0.65 1,172 762 1,900 12/08/22
RAMSAY DAVID A Director Director Sep 23 Buy 1.39 135,000 187,650 1,876,142 09/27/22
RAMSAY DAVID A Director Director Sep 06 Buy 1.39 32,000 44,480 1,733,142 09/08/22
RAMSAY DAVID A Director Director Jun 17 Buy 1.38 100,000 138,000 1,601,142 06/22/22
RAMSAY DAVID A Director Director Aug 19 Buy 1.19 97,290 115,775 964,090 08/19/21
Chowdhury Badrul A. CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER May 17 Option 0 200,000 200,000 05/17/21
Chowdhury Badrul A. CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER May 17 Sell 1.56 50,000 78,000 150,000 05/17/21